8-K: SELLAS Life Sciences Q2 2026 Update: Promising Trial Data, Strong Cash

SELLAS Life Sciences Group reported Q2 2026 results, highlighting progress in Phase 3 REGAL trial for GPS and Phase 2 for SLS009, with topline data expected Q4 2026, alongside a robust cash reserve of $138.3 million.

Summary

• SELLAS Life Sciences Group announced its financial results for the second quarter ended June 30, 2026.
• The company is nearing the 80th event in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML), which will trigger final analysis and potentially a Biologics License Application (BLA) submission.
• Enrollment and dosing are progressing in the Phase 2 trial of SLS009 in newly diagnosed AML patients, with topline data anticipated in Q4 2026.
• Preclinical studies show promising efficacy for SLS009 in pancreatic cancer resistant to RAS inhibitors, with clinical development preparations underway.
• As of June 30, 2026, the company held $138.3 million in cash and cash equivalents.
• Research and development expenses increased to $6.3 million for Q2 2026 from $3.9 million in Q2 2025, driven by manufacturing, clinical, and regulatory costs.
• General and administrative expenses rose to $4.4 million for Q2 2026 from $3.0 million in Q2 2025, attributed to professional fees and stock-based compensation.
• The net loss for Q2 2026 was $9.6 million ($0.05 per share), compared to a net loss of $6.6 million ($0.07 per share) in Q2 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a cautiously optimistic report, with significant progress in clinical trials and a strong cash position, balanced by increasing operational expenses and net losses.

Positives

• Approaching critical milestone in Phase 3 REGAL trial for GPS, potentially leading to BLA submission.
• Enrollment in Phase 2 SLS009 AML trial is tracking ahead of industry standards.
• Strong cash and cash equivalents position of $138.3 million as of June 30, 2026, providing financial runway.
• Promising preclinical data for SLS009 in advanced pancreatic cancer.
• SLS009 shows potential as a single agent and in combination therapies for AML with unfavorable prognostic factors.

Negatives

• Net loss increased to $9.6 million in Q2 2026 from $6.6 million in Q2 2025.
• Research and development expenses increased significantly to $6.3 million in Q2 2026 from $3.9 million in Q2 2025.
• General and administrative expenses also increased to $4.4 million in Q2 2026 from $3.0 million in Q2 2025.
• Basic and diluted loss per share was $0.05 for Q2 2026, compared to $0.07 for Q2 2025.

Risks

• The REGAL trial's final analysis is contingent on the occurrence of the 80th event, with no guaranteed timeline.
• Clinical trial success for GPS and SLS009 is not assured and is subject to inherent risks and uncertainties in oncology product development.
• Regulatory approval for GPS is uncertain.
• The company faces risks and uncertainties affecting its development programs as detailed in its Form 10-K filed March 19, 2026.
• Unforeseen risks and uncertainties not currently known to SELLAS may impact future results.

Future Outlook

Topline data for the Phase 2 trial of SLS009 in newly diagnosed AML is expected in Q4 2026. The company is preparing for clinical development of SLS009 in pancreatic cancer. The final analysis of the Phase 3 REGAL trial for GPS is contingent on the 80th event, which will trigger database lock and data review, potentially leading to a BLA submission.

Management Comments

• "The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009."
• "For GPS, we are approaching the pre-specified 80th event in the Phase 3 REGAL trial marking a critical step toward the final efficacy analysis and, if successful, a potential BLA submission to the FDA."
• "At the same time, we are making meaningful progress with SLS009 in our ongoing Phase 2 frontline AML study, where dosing continues and enrollment is tracking ahead of industry standards, with topline data expected in the fourth quarter of 2026."
• "In addition, we have obtained promising results from preclinical studies in pancreatic ductal adenocarcinoma (PDAC) and intend to support clinical development at a top-tier academic institution."
• "Together, these programs reflect our commitment to developing differentiated therapies that may address significant unmet needs for patients with AML and support meaningful long-term value creation for SELLAS."

Industry Context

StockSavvy.ai notes that SELLAS's progress aligns with the broader biopharmaceutical industry's focus on developing targeted therapies for challenging cancers like AML and pancreatic cancer. The increasing R&D expenses reflect the significant investment required for late-stage clinical development and regulatory preparations, a common trend among companies in this sector.

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and regulatory approvals are obtained, but also face risks associated with increased net losses and R&D spending.
• Patients: Potential for new therapeutic options for AML and pancreatic cancer if GPS and SLS009 prove effective and safe.
• Creditors: The company's strong cash position suggests it can meet its short-term obligations.

Next Steps

• Trigger database lock and blinded data review for the Phase 3 REGAL trial upon the 80th event.
• Disclose topline results from the Phase 3 REGAL trial following data review.
• Submit a potential Biologics License Application (BLA) to the FDA for GPS if the REGAL study is successful.
• Continue dosing and enrollment in the Phase 2 trial of SLS009 in newly diagnosed AML patients.
• Present preclinical data for SLS009 in pancreatic cancer at an upcoming medical conference.
• Support clinical development of SLS009 in pancreatic cancer at a top-tier academic institution.

Key Dates

Recommendation

The company is making significant progress in its clinical pipeline with strong preclinical data and approaching key milestones in its Phase 3 trial. However, the increasing net losses and R&D expenses, coupled with the inherent uncertainties of drug development and regulatory approval, warrant a 'hold' recommendation until further data and regulatory outcomes are clearer.

Keywords

Acute Myeloid Leukemia, Galinpepimut-S, GPS, SLS009, CDK9 inhibitor, Pancreatic Cancer, Clinical Trials, Biopharmaceutical